AC Immune SA (ACIU)

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company that specializes in developing treatments for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Down syndrome. The company uses proprietary technology platforms to discover, design, and develop therapeutic and diagnostic products for protein misfolding diseases. AC Immune's pipeline includes small molecules, biologics, and vaccines. The company has collaborations with several pharmaceutical and biotech companies to develop and commercialize its products. AC Immune was founded in 2003 and is headquartered in Lausanne, Switzerland. The company is listed on the NASDAQ stock exchange under the ticker symbol ACIU.